Ohio

CDC advisors meet with COVID-19 boosters to discuss the safety of J & J vaccines

Vaccine advisors from the US Centers for Disease Control and Prevention meet Thursday to make recommendations on how to address new safety issues with the Johnson & Johnson COVID-19 vaccine, with COVID-19 vaccine boosters in the future — especially the immune system For those who are. The Advisory Committee on Immunization and Implementation (ACIP) will meet from 11:00 am to 4:30 pm. The panel has no plans to vote on issues on the agenda. ACIP is a panel of external healthcare professionals in vaccination, immunology, pediatrics, internal medicine, nursing, virology, public health, infectious diseases and other disciplines. .. The CDC usually accepts its recommendations once a vote is taken. ACIP is due to an emergency use authorization for the three COVID-19 vaccines currently available in the United States, a Pfizer vaccine authorization for 12 to 15 years of age, and a rare blood coagulation disorder that occurred in a small number of vaccinated individuals in April. The suspension of J & J vaccine will be terminated. On Thursday, ACIP will address some new issues regarding the safety and durability of the COVID-19 vaccine. First, ACIP reviews recent data on cases of Guillain-Barré syndrome (GBS) in people vaccinated with COVID-19 with the J & J coronavirus vaccine. Federal health officials have reported cases of GBS (a rare neuropathy in which the body’s immune system damages nerve cells, causing weakness and temporary paralysis) among approximately 13 million people who have been vaccinated. It states that there were about 100 preliminary reports. The US Food and Drug Administration has already updated the J & J vaccine label last week to list GBS as a rare risk. Given this adverse event, the ACIP discussion focuses on the question of whether the benefits of the J & J vaccine still outweigh the risks of GBS. Tomorrow’s meeting was triggered by this newly identified adverse event, Dr. William Schaffner, a professor and ACIP member of the Infectious Diseases Division at Vanderbilt University Medical Center, told CNN. “There is no formal vote and you will come to the conclusion that Covid’s risk is very high and the vaccine’s risk is very low. In fact, it’s very low,” he added. ACIP also undertakes the subject of coronavirus vaccines. Booster immunization prioritizes a review of data on the need for booster vaccines for people who are immune-protected. Recent reports suggest that the COVID-19 vaccine is not sufficiently effective for people with weakened immunity, and last week the CDC revised its guidance for fully vaccinated individuals. Did. People with immunodeficiency are advised to warn that the vaccine may be less effective and to continue safety measures as if they were not vaccinated. However, the CDC has not yet officially recommended boosters to anyone. The goal of ACIP is to consider the need for boosters and to see the data currently available and publicly available. “Tomorrow shows that there is very little evidence,” says Schaffner. This ultimately means that the group will not vote for boosters. Earlier this month, Pfizer announced that it would seek permission to provide a third dose of COVID-19. The vaccine as a booster cites data from Israel on the continued spread of the coronavirus and its limited efficacy against the more contagious delta variant. Health officials, including Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, continued to say: The United States needs more data before recommending a colonavirus vaccine booster to anyone. “The CDC and FDA have said they don’t need a boost based on currently known data,” Fauci told CNN last week. “That doesn’t mean it doesn’t change. In fact, we may need to give boosters to certain selected groups, such as the elderly or groups with underlying illnesses, either entirely or at some point. Hmm.”

Vaccine advisors from the US Centers for Disease Control and Prevention meet Thursday to make recommendations on how to address new safety issues with Johnson & Johnson’s COVID-19 vaccine, with COVID-19 vaccine boosters in the future—especially the immune system. For those who are declining.

The Advisory Committee on Immunization Implementation (ACIP) will meet from 11:00 am to 4:30 pm Eastern Standard Time. The panel has no plans to vote on issues on the agenda.

ACIP is a panel of external healthcare professionals in vaccination, immunology, pediatrics, internal medicine, nursing, virology, public health, infectious diseases and other disciplines. The CDC usually accepts its recommendations once a vote is taken.

ACIP provides important guidance throughout the pandemic, including an emergency use authorization for the three COVID-19 vaccines currently available in the United States, a Pfizer vaccine authorization for ages 12-15, and the termination of the J & J suspension in April. It offers. A vaccine due to a rare blood coagulation disorder that occurred in a small number of vaccinated people.

On Thursday, ACIP will address some new issues regarding the safety and durability of the COVID-19 vaccine. First, ACIP reviews recent data on cases of Guillain-Barré syndrome (GBS) in people vaccinated with COVID-19 with the J & J coronavirus vaccine.Federal health officials say there were about 100 preliminary reports Case Among about 13 million people vaccinated with GBS (a rare neuropathy in which the body’s immune system damages nerve cells, causing weakness and temporary paralysis).

The US Food and Drug Administration has already updated the J & J vaccine label last week to list GBS as a rare risk. Given this adverse event, the ACIP discussion focuses on the question of whether the benefits of the J & J vaccine still outweigh the risks of GBS. ACIP is expected to say so.

Tomorrow’s meeting was triggered by this newly identified adverse event, Dr. William Schaffner, a professor and ACIP member of the Infectious Diseases Division at Vanderbilt University Medical Center, told CNN. “There is no formal vote and you will come to the conclusion that Covid’s risk is very high and the vaccine’s risk is very low. In fact, it’s very low,” he added.

ACIP also undertakes the subject of coronavirus vaccine boosters, prioritizing a review of data on the need for booster vaccines for immunocompromised people. Recent reports suggest that the COVID-19 vaccine is not sufficiently effective for people with weakened immunity, and last week the CDC revised its guidance for fully vaccinated individuals. Did. People with immunodeficiency are advised to warn that the vaccine may be less effective and to continue safety measures as if they were not vaccinated. However, the CDC has not yet officially recommended boosters to anyone.

The goal of ACIP is to consider the need for boosters and to see the data currently available and publicly available. “what [ACIP] Tomorrow we will show that there is very little evidence, “says Schaffner. This ultimately means that the group will not vote for boosters.

Earlier this month, Pfizer announced that it was seeking permission to provide a third dose of the COVID-19 vaccine as a booster. It cites Israeli data on the continued epidemic of coronavirus and its limited efficacy against the more contagious delta mutants.

Health officials, including Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, continue to say that the United States needs more data before recommending a coronavirus vaccine booster to anyone.

“The CDC and FDA have said no boost is needed based on the data we currently know,” Fauci told CNN last week. “That doesn’t mean it doesn’t change. In fact, we may need to give boosters to certain selected groups, such as the elderly or groups with underlying illnesses, either entirely or at some point. Hmm.”

CDC advisors meet with COVID-19 boosters to discuss the safety of J & J vaccines

Source link CDC advisors meet with COVID-19 boosters to discuss the safety of J & J vaccines

Related Articles

Back to top button